Research map: Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice

Back to the article

Papers in this map

  1. Fiji: an open-source platform for biological-image analysis · Johannes Schindelin · 2012 · 73297 citations · Cited by this paper
  2. Leave No Data Behind: Exploring a new paradigm in oncology with foundation models and large language models · 2026 · Related
  3. Understanding the mechanisms and treatment options in cancer cachexia · Kenneth C. H. Fearon · 2012 · 963 citations · Cited by this paper
  4. Self-sufficient killing of malignant tumors by an engineered cancer-selective gene circuit · 2026 · Related
  5. Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS · Jonathan S. Mill · 2022 · 942 citations · Cited by this paper
  6. Persistent cytolytic CD8+ T cells recognize SARS-CoV-2 and herpesvirus epitopes in long COVID · 2026 · Related
  7. Antisense oligonucleotides: the next frontier for treatment of neurological disorders · Carlo Rinaldi · 2017 · 810 citations · Cited by this paper
  8. Repurposed ethoxzolamide reprograms antitumor immunity through β-TrCP-dependent PD-L1 ubiquitination · 2026 · Related
  9. GFRAL is the receptor for GDF15 and the ligand promotes weight loss in mice and nonhuman primates · Shannon E. Mullican · 2017 · 796 citations · Cited by this paper
  10. Combine antibody-drug conjugate with cmLumiOpto for triple-negative breast cancer treatment · 2026 · Related
  11. A Switch from White to Brown Fat Increases Energy Expenditure in Cancer-Associated Cachexia · Michele Petruzzelli · 2014 · 769 citations · Cited by this paper
  12. Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4+CD8+ T cells · 2026 · Related
  13. Antisense technology: an overview and prospectus · Stanley T. Crooke · 2021 · 765 citations · Cited by this paper
  14. Köhlmeier-Degos disease is an interferonopathy characterized by type I and II interferon-driven inflammatory vasculopathy · 2026 · Related
  15. Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia · Serkan Kır · 2014 · 698 citations · Cited by this paper
  16. Metabolomic and lifestyle profiles refine BMI-metabolic phenotypes in older adults · 2026 · Related
  17. GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand · Linda G. Yang · 2017 · 689 citations · Cited by this paper
  18. Alterations of the host-lung microbiome metasystem in systemic inflammatory response syndrome is associated with secondary pneumonia · 2026 · Related
  19. The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL · Paul J. Emmerson · 2017 · 688 citations · Cited by this paper
  20. An autonomous multimodal AI agent for evidence-grounded ophthalmic diagnosis · 2026 · Related
  21. Muscle type and fiber type specificity in muscle wasting · Stefano Ciciliot · 2013 · 645 citations · Cited by this paper
  22. Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1 · Heiko Johnen · 2007 · 615 citations · Cited by this paper
  23. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals · Eric E. Swayze · 2006 · 479 citations · Cited by this paper
  24. The MIC-1/GDF15-GFRAL Pathway in Energy Homeostasis: Implications for Obesity, Cachexia, and Other Associated Diseases · Vicky Wang-Wei Tsai · 2018 · 436 citations · Cited by this paper
  25. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia · Sara Peixoto da Silva · 2020 · 384 citations · Cited by this paper
  26. Ponsegromab for the Treatment of Cancer Cachexia · John D. Groarke · 2024 · 307 citations · Cited by this paper
  27. GDF15 Induces Anorexia through Nausea and Emesis · Tito Borner · 2020 · 254 citations · Cited by this paper
  28. Plasma growth differentiation factor 15 is associated with weight loss and mortality in cancer patients · Lorena R. Lerner · 2015 · 210 citations · Cited by this paper
  29. MAP3K11/GDF15 axis is a critical driver of cancer cachexia · Lorena R. Lerner · 2015 · 190 citations · Cited by this paper
  30. Insights Into Mechanisms of GDF15 and Receptor GFRAL: Therapeutic Targets · Luc Rochette · 2020 · 190 citations · Cited by this paper
  31. Body composition and lung cancer-associated cachexia in TRACERx · Othman Al‐Sawaf · 2023 · 146 citations · Cited by this paper
  32. Synthesis, biophysical properties and biological activity of second generation antisense oligonucleotides containing chiral phosphorothioate linkages · W. Brad Wan · 2014 · 130 citations · Cited by this paper
  33. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours · Ignacio Melero · 2024 · 125 citations · Cited by this paper
  34. Activation of GPR81 by lactate drives tumour-induced cachexia · Xidan Liu · 2024 · 120 citations · Cited by this paper
  35. GDF15 neutralization restores muscle function and physical performance in a mouse model of cancer cachexia · Ja Young Kim-Muller · 2023 · 112 citations · Cited by this paper
  36. Antisense oligonucleotide therapy reduces seizures and extends life span in an SCN2A gain-of-function epilepsy model · Melody Li · 2021 · 109 citations · Cited by this paper
  37. Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment · Markus Haake · 2023 · 108 citations · Cited by this paper
  38. Phenotypic features of cancer cachexia‐related loss of skeletal muscle mass and function: lessons from human and animal studies · Agnès Martin · 2021 · 104 citations · Cited by this paper
  39. GFRAL-expressing neurons suppress food intake via aversive pathways · Paul V. Sabatini · 2021 · 101 citations · Cited by this paper

Source: OpenAlex (CC0)